NETHERLANDS - APG Investments, the asset manager of giant Dutch pension fund ABP, will invest together with the Life Sciences Partner Group in the European publicly-listed small-cap biotech market.

APG has entered into a relationship with the biotechnology investment group, to increase its investment focus on the investments, according to Martin Eijgenhuijsen, senior portfolio manager healthcare at the asset manager.

A spokesman for the fund manager told IPE APG has virtually no exposure to the small-cap biotech market in its internally-managed portfolios.

In the external portfolios, which combined amount to approximately 20% of APG's €217bn managed assets, the manager has around €50m invested in small-cap biotech, spokesman Eijgenhuijsen added: "APG Investments believes that Europe is an increasingly fertile location for biotechnology companies and the LSP team's skills and expertise in healthcare investing make them a strong partner."

Mark Wegter, general partner at LSP and responsible for the firm's recently-established public biotech franchise, commented: "The relationship with APG Investments is based upon our joint belief that the highly innovative and hugely dynamic biotechnology sector requires specialized investment expertise and knowledge."

If you have any comments you would like to add to this or any other story, contact Carolyn Bandel on +44 (0)20 7261 4622 or email